NCT03920072 - Study of the Anti-FGF23 Antibody, Burosumab, in Adults With XLH | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 7, 2019

Primary Completion Date

April 7, 2022

Study Completion Date

April 7, 2022

Conditions

X-linked Hypophosphatemia

Interventions

DRUG

Burosumab

Burosumab is a sterile, clear, colourless and preservative free solution supplied in single-use 5ml vials containing 1mL of burosumab at a concentration of 30mg/mL

Trial Locations (10)

50139

Azienda ospedaliera universitaria Careggi, Florence

75010

Hopital Lariboisiere, Paris

75014

Hopital Cochin, Paris

94275

CHU de Bicetre, Le Kremlin-Bicêtre

D04 T6F4

St. Vincent's University Hospital, Dublin

EH4 2XU

Western General Hospital, Edinburgh

WC1N 3BG

National Hospital for Neurology and Neurosurgery-University College London Hospitals NHS Foundation Trust, London

OX3 7LD

Nuffield Orthopaedic Centre - Oxford University Hospitals Nhs Trust, Oxford

S5 7AU

Northen General Hospital, Sheffield

HA7 4LP

Royal National Orthopaedic Hospital NHS Trust, Stanmore